SNY catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedPhase 2NCT05039840Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus ErythematosusSanofi · Systemic Lupus ErythematosusActive, not recruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Sep 4, 2026Actual
- Interventions
- Locked
- Completion LockedNo phase registeredNCT07905534A Retrospective Cohort Study Evaluating Major Adverse Cardiovascular Events and Cardiovascular Outcomes in Adults With Atherosclerotic...Sanofi · Atherosclerotic Cardiovascular DiseaseActive, not recruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Aug 21, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT07216079Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in JapanSanofi · Immune ThrombocytopeniaActive, not recruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Nov 25, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT06838000Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy...Sanofi Pasteur, a Sanofi Company · Pneumococcal InfectionsActive, not recruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Dec 1, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT06907511Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic...Sanofi · Pandemic Influenza ImmunizationActive, not recruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Dec 1, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT05588843Dose-finding Study of SAR443122 in Adult Participants With Ulcerative ColitisSanofi · Colitis UlcerativeActive, not recruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Feb 10, 2026Actual
- Interventions
- Locked
- Completion LockedNo phase registeredNCT06258057Safety of Tetanus, Diphtheria, Acellular Pertussis With 5 Acellular Pertussis Components (Tdap5) Vaccination During PregnancySanofi · Pertussis (Whooping Cough)Active, not recruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Dec 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT05206773A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age...Sanofi · Fabry DiseaseActive, not recruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Dec 17, 2025Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT04644575Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia ABioverativ, a Sanofi company · Hemophilia AActive, not recruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Jan 15, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT06686654Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based...Sanofi Pasteur, a Sanofi Company · Human Metapneumovirus ImmunizationActive, not recruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Jan 18, 2027Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 4NCT07861542Study of a Recombinant Spike COVID-19 Vaccine With Matrix-M in Older Adults and People at Increased Risk of Severe COVID-19Sanofi · COVID-19Active, not recruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Nov 26, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 3NCT06834360A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With...Sanofi · Chronic Rhinosinusitis With Nasal PolypsActive, not recruitingSNYLeadREGNCollaborator
- Enrollment
- Locked
- Primary completion
- Sep 24, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 3NCT07424144An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled...Sanofi · Chronic Rhinosinusitis With Nasal PolypsActive, not recruitingSNYLeadREGNCollaborator
- Enrollment
- Locked
- Primary completion
- Feb 17, 2027Sponsor estimate
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 13 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.